Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology

Several clinical trials have recently targeted specific pathways implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, IPF remains plagued by a median survival of 3 yrs and emphasises the need for further research with new insights and perspectives. The prevailing pathogenic hypotheses assume that either an inflammatory process or an independent epithelial/fibroblastic disorder may propagate the disease process. Based on knowledge developed with considerable scientific evidence, we provide our perspectives with an alternative point of view that IPF be considered as a neoproliferative disorder of the lung. Genetic alterations, response to growth and inhibitory signals, resistance to apoptosis, myofibroblast origin and behaviour, altered cellular communications, and intracellular signalling pathways are all fundamental pathogenic hallmarks of both IPF and cancer. The concept of IPF as a lethal malignant disorder of the lung might extend beyond the pathogenic link between these two diseases and disclose new pathogenic mechanisms leading to novel therapeutic options, adopted from cancer biology. Moreover, this vision might dawn the awareness of the public, political and scientific community of this devastating disease from an angle different from the current perception and provoke new ideas and studies to get a better understanding to control the otherwise relentless progressive disease.

[1]  R. Bucala,et al.  The role of circulating fibrocytes in fibrosis , 2006, Current rheumatology reports.

[2]  T. Hunt,et al.  Bone Marrow Contribution to Tumor-Associated Myofibroblasts and Fibroblasts , 2004, Cancer Research.

[3]  K. Kuwano,et al.  P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.

[4]  C. Vancheri,et al.  Different Expression of TNF- α Receptors and Prostaglandin E2Production in Normal and Fibrotic Lung Fibroblasts , 2000 .

[5]  F. Nicoletti,et al.  TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. , 2008, Pharmacological research.

[6]  Khalid Shah,et al.  Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. , 2008, The Lancet. Oncology.

[7]  A. Nicholson,et al.  A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. , 1999, American journal of respiratory and critical care medicine.

[8]  C. Vancheri,et al.  Different expression of TNF-alpha receptors and prostaglandin E(2 )Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. , 2000, American journal of respiratory cell and molecular biology.

[9]  J. Norris,et al.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. , 2007, American journal of respiratory and critical care medicine.

[10]  K. Brown,et al.  Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. , 2006, American journal of respiratory and critical care medicine.

[11]  W. MacNee,et al.  Oxidative stress and regulation of glutathione in lung inflammation. , 2000, The European respiratory journal.

[12]  V. Poletti,et al.  Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .

[13]  A. Trovato-Salinaro,et al.  Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis , 2006, Respiratory research.

[14]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[15]  J. Stewart,et al.  Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. , 2001, Respiratory medicine.

[16]  J. Fujita,et al.  Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. , 1998, The European respiratory journal.

[17]  N. Sharifi Commentary: Antioxidants for cancer: new tricks for an old dog? , 2009, The oncologist.

[18]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[19]  G. Raghu,et al.  Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. , 1989, The American review of respiratory disease.

[20]  E. Kleinerman,et al.  Murine bone marrow–derived mesenchymal stem cells as vehicles for interleukin‐12 gene delivery into Ewing sarcoma tumors , 2009, Cancer.

[21]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[22]  U. Pastorino,et al.  Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer , 2003, British Journal of Cancer.

[23]  M. Andreeff,et al.  Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles , 2007, International journal of hematology.

[24]  Carlos L. Arteaga,et al.  Targeting the TGFβ signaling network in human neoplasia , 2003 .

[25]  F. Spinella,et al.  The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. , 2008, Canadian journal of physiology and pharmacology.

[26]  V. Poletti,et al.  Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis , 2006, Respiratory research.

[27]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[28]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[29]  M. Andreeff,et al.  Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.

[30]  S. Hirohashi,et al.  Increased expression of laminin‐5 and its prognostic significance in lung adenocarcinomas of small size , 2001, Cancer.

[31]  M. Rojas,et al.  Bone marrow-derived mesenchymal stem cells in repair of the injured lung. , 2005, American journal of respiratory cell and molecular biology.

[32]  A. Yoshimura,et al.  Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. , 2001, Cancer research.

[33]  Mary R. Myerscough,et al.  Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions , 2007, Clinical & Experimental Metastasis.

[34]  M. Burdick,et al.  Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. , 2007, Biochemical and biophysical research communications.

[35]  J. Hagood,et al.  Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. , 2007, American journal of respiratory cell and molecular biology.

[36]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[37]  G. Raghu,et al.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[38]  Chao Xing,et al.  Adult-onset pulmonary fibrosis caused by mutations in telomerase , 2007, Proceedings of the National Academy of Sciences.

[39]  A. Georgakilas,et al.  Oxidative stress, DNA methylation and carcinogenesis. , 2008, Cancer letters.

[40]  G. Raghu,et al.  Telomere shortening in familial and sporadic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[41]  F. Ishikawa,et al.  Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. , 2007, The Journal of clinical investigation.

[42]  R. D. du Bois,et al.  Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. , 2007, Arthritis and rheumatism.

[43]  C. Vogelmeier,et al.  Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. , 1997, American journal of respiratory and critical care medicine.

[44]  V. Keshamouni,et al.  Activation of the Pro-survival Phosphatidylinositol 3-Kinase/AKT Pathway by Transforming Growth Factor-β1 in Mesenchymal Cells Is Mediated by p38 MAPK-dependent Induction of an Autocrine Growth Factor* , 2004, Journal of Biological Chemistry.

[45]  G. Kroemer,et al.  HSP27 and HSP70: Potentially Oncogenic Apoptosis Inhibitors , 2003, Cell cycle.

[46]  G. Saed,et al.  Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. , 1998, Archives of dermatology.

[47]  B. Alving,et al.  Update in Hematology , 2001, Annals of Internal Medicine.

[48]  A. Malkinson,et al.  Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. , 1998, Carcinogenesis.

[49]  A. Nicholson,et al.  The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.

[50]  G. Berx,et al.  Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front , 2008, Histochemistry and Cell Biology.

[51]  S. Mutsaers,et al.  Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta isoforms on fibroblast cell cultures. , 1997, The Biochemical journal.

[52]  B. Johansson,et al.  Multicolor fluorescence in situ hybridization characterization of cytogenetically polyclonal hematologic malignancies. , 2005, Cancer genetics and cytogenetics.

[53]  G. Nuovo,et al.  Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. , 2008, American journal of respiratory cell and molecular biology.

[54]  J. Horowitz,et al.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[55]  V. Poletti,et al.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. , 2003, The American journal of pathology.

[56]  D. O'Gorman,et al.  Beta-catenin signaling in fibroproliferative disease. , 2007, The Journal of surgical research.

[57]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[58]  A. Nagler,et al.  Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect , 2007, Molecular Cancer Therapeutics.

[59]  C. Henke,et al.  β1 Integrin Regulates Fibroblast Viability during Collagen Matrix Contraction through a Phosphatidylinositol 3-Kinase/Akt/Protein Kinase B Signaling Pathway* , 2002, The Journal of Biological Chemistry.

[60]  M. Jordana,et al.  Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. , 1988, The American review of respiratory disease.

[61]  Barbara L Parsons,et al.  Many different tumor types have polyclonal tumor origin: evidence and implications. , 2008, Mutation research.

[62]  H. Yamasaki,et al.  Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. , 2004, Carcinogenesis.

[63]  G. Hunninghake Antioxidant therapy for idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[64]  K. Chida,et al.  Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. , 2006, Chest.

[65]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[66]  Biao He,et al.  Wnt signaling in lung cancer. , 2005, Cancer letters.

[67]  M. Burdick,et al.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.

[68]  E. White,et al.  Bleomycin-Induced E Prostanoid Receptor Changes Alter Fibroblast Responses to Prostaglandin E21 , 2005, The Journal of Immunology.

[69]  D. Spandidos,et al.  MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis , 2002, Journal of cellular and molecular medicine.

[70]  K. Surendran,et al.  A role for Wnt-4 in renal fibrosis. , 2002, American journal of physiology. Renal physiology.

[71]  A. Ostman,et al.  Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? , 2004, Lung cancer.

[72]  A. Lazar,et al.  Desmoid tumor: a disease opportune for molecular insights. , 2008, Histology and histopathology.

[73]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[74]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[75]  Michael Koval,et al.  Cross-talk between pulmonary injury, oxidant stress, and gap junctional communication. , 2009, Antioxidants & redox signaling.

[76]  G. Giaccone,et al.  Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Y. Atomi,et al.  Coexpression of Matrilysin and Laminin-5 γ2 Chain May Contribute to Tumor Cell Migration in Colorectal Carcinomas , 2003, Digestive Diseases and Sciences.

[78]  Paul Martin,et al.  Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration , 2006, Journal of Cell Science.

[79]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[80]  G. Raghu,et al.  Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. , 1988, The American review of respiratory disease.

[81]  D. O'Gorman,et al.  β-Catenin Signaling in Fibroproliferative Disease , 2007 .

[82]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[83]  K. Adler,et al.  The myofibroblast in pulmonary fibrosis. , 1983, Chest.